Bavencio Disease Interactions
There are 10 disease interactions with Bavencio (avelumab).
- Hepatic impairment
- Adrenal insufficiency
- Colitis
- Diabetes
- Pneumonitis
- Renal dysfunction
- Thyroid disease
- HSCT
- Myasthenia gravis
- Organ transplant
Avelumab (applies to Bavencio) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
No clinically meaningful differences in pharmacokinetics were observed in the clearance of avelumab based on mild or moderate hepatic impairment. Caution should be exercised when avelumab is used in patients with severe hepatic impairment as there are limited data from patients. The effect of severe hepatic impairment on the pharmacokinetics of avelumab is unknown.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) adrenal insufficiency
Moderate Potential Hazard, Moderate plausibility.
Avelumab can cause immune-mediated adrenal insufficiency. Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc. It is recommended to administer corticosteroids as appropriate for adrenal insufficiency. Monitor patients for clinical signs and symptoms of adrenal insufficiency and institute appropriate measures as necessary. Withhold avelumab for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. If appropriate modify the dose according to manufacturer recommendations. Monitor as clinically indicated prior to and periodically during treatment. Care should be taken when using avelumab in these patients.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) colitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Inflammatory Bowel Disease
Immune-mediated colitis has been reported with the use of avelumab. It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for moderate or severe or life-threatening colitis. If appropriate modify the dose according to manufacturer recommendations. Monitor patients for signs and symptoms of colitis. Permanently discontinue avelumab for life-threatening or for recurrent colitis. Care should be taken when using avelumab in patients with inflammatory bowel disease.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Avelumab can cause type 1 diabetes mellitus. Monitor for hyperglycemia or other signs and symptoms of diabetes. Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved. Permanently discontinue avelumab for life-threatening hyperglycemia. If appropriate modify the dose according to manufacturer recommendations. Care should be exercised when using avelumab in diabetic patients.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pleuropulmonary Infection
Immune-mediated pneumonitis, including fatal cases have been reported with the use of avelumab. Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis. It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate or more severe pneumonitis, followed by corticosteroid taper. Withhold treatment with avelumab for moderate pneumonitis and permanently discontinue therapy for severe, life-threatening, or recurrent moderate pneumonitis. If appropriate modify the dose according to manufacturer recommendations. Care should be taken when using avelumab in patients with pulmonary infections.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Avelumab can cause immune-mediated nephritis. Monitor patients for elevated serum creatinine prior to and periodically during treatment. It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for life-threatening increased serum creatinine. Withhold avelumab for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to <= Grade 1. Permanently discontinue avelumab for life-threatening (Grade 4) nephritis. If appropriate modify the dose according to manufacturer recommendations. Care should be taken when using avelumab in patients with renal dysfunction.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
Avelumab (applies to Bavencio) thyroid disease
Moderate Potential Hazard, Moderate plausibility.
Avelumab can cause autoimmune thyroid disorders. Monitor thyroid function prior to and periodically during treatment. Administer hormone-replacement therapy for hypothyroidism. Initiate medical management for control of hyperthyroidism. It is recommended to withhold avelumab for severe (Grade 3) or life-threatening (Grade 4) thyroid disorders. Care should be taken when using this agent in patients with thyroid disease.
References
- "Product Information. Bavencio (avelumab)." EMD Serono Inc (2017):
PD-1/PD-L1 inhibitors (applies to Bavencio) HSCT
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Transplantation
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.
References
- "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb SUPPL-119 (2023):
- "Product Information. Zynyz (retifanlimab)." Incyte Corporation ORIG-1 (2023):
- "Product Information. Keytruda (pembrolizumab)." Merck Sharp & Dohme LLC SUPPL-136 (2023):
- "Product Information. Libtayo (cemiplimab)." Regeneron Pharmaceuticals Inc SUPPL-16 (2023):
- "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline SUPPL-6 (2023):
- "Product Information. Tecentriq (atezolizumab)." Genentech SUPPL-51 (2023):
- "Product Information. Bavencio (avelumab)." EMD Serono Inc SUPPL-13 (2022):
- "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals SUPPL-42 (2023):
PD-1/PD-L1 inhibitors (applies to Bavencio) myasthenia gravis
Moderate Potential Hazard, Moderate plausibility.
Myasthenic syndrome/myasthenia gravis (including exacerbation) has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients with myasthenia gravis.
References
- "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb SUPPL-119 (2023):
- "Product Information. Zynyz (retifanlimab)." Incyte Corporation ORIG-1 (2023):
- "Product Information. Keytruda (pembrolizumab)." Merck Sharp & Dohme LLC SUPPL-136 (2023):
- "Product Information. Libtayo (cemiplimab)." Regeneron Pharmaceuticals Inc SUPPL-16 (2023):
- "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline SUPPL-6 (2023):
- "Product Information. Tecentriq (atezolizumab)." Genentech SUPPL-51 (2023):
- "Product Information. Bavencio (avelumab)." EMD Serono Inc SUPPL-13 (2022):
- "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals SUPPL-42 (2023):
PD-1/PD-L1 inhibitors (applies to Bavencio) organ transplant
Moderate Potential Hazard, Moderate plausibility.
Solid organ transplant rejection has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ transplant.
References
- "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb SUPPL-119 (2023):
- "Product Information. Zynyz (retifanlimab)." Incyte Corporation ORIG-1 (2023):
- "Product Information. Keytruda (pembrolizumab)." Merck Sharp & Dohme LLC SUPPL-136 (2023):
- "Product Information. Libtayo (cemiplimab)." Regeneron Pharmaceuticals Inc SUPPL-16 (2023):
- "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline SUPPL-6 (2023):
- "Product Information. Tecentriq (atezolizumab)." Genentech SUPPL-51 (2023):
- "Product Information. Bavencio (avelumab)." EMD Serono Inc SUPPL-13 (2022):
- "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals SUPPL-42 (2023):
Bavencio drug interactions
There are 6 drug interactions with Bavencio (avelumab).
More about Bavencio (avelumab)
- Bavencio consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.